admin

DURHAM, N.C. --(BUSINESS WIRE)--May 12, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022 , the Compensation Committee of Precision’s

- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo Gene Editing Data for Primary Hyperoxaluria Type 1 and Chronic Hepatitis B

- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS ® gene editing therapies DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ®

Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing

- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the American Society of Hematology Meeting Showing High Response Rates to PBCAR0191 in Heavily Treated

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and

DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that Michael Amoroso , Chief Executive

DURHAM, N.C. --(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with

- Precision BioSciences is Simultaneously Advancing Development of PBCAR0191, as Potential First-in-Class, and PBCAR19B as Potential Best-in-Class CD19 Targeting Allogeneic CAR T Therapies - High Response Rates to PBCAR0191 Observed in Heavily Treated Patients Who Relapsed Following Prior

DURHAM, N.C. --(BUSINESS WIRE)--Dec. 6, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at